Stories on the potential health savings if more people quit smoking, and Louisiana's failed attempt to put nursing homes in managed care.
A 10-year study has found that patients who develop colon cancer on the left side survive longer than those who have cancer strike on the right side. The study’s principal author, Alan P. Venook, MD, of the University of California San Francisco (UCSF) said, “All colon cancer is not created equally,” and the findings also show standard treatment performs much better on patients whose cancer appears on the left side. Full results will be presented at the upcoming meeting of the American Society of Clinical Oncology.
If 10% of American smokers quit and the others cut the habit by 10%, the United States could save $63 billion a year in medical costs. That’s the finding of an analysis by noted tobacco researcher Stanton Glantz, PhD, of UCSF’s Center for Tobacco Research Control and Education. Glantz told Reuters, “You start to see the benefits so quickly, and they’re huge because healthcare costs are so gigantic.”
Louisiana’s struggles to prioritize healthcare spending amid a budget crisis continue. On Tuesday, legislation that would have put the state’s famously powerful nursing home industry under managed care died in committee, amid opposition from the industry lobby. The projected savings had been $31 million the first year and $430 million over 5 years. The state has among the highest nursing home admissions for patients with limited needs.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients
January 13th 2025Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
January 2nd 2025Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Read More